[1] Tenofovir disoproxil fumarate (Viread, Gilead Sciences, Inc.) is a new addition to the antiretroviral armamentarium. It is an ester-derived prodrug that is converted in vivo by serum and ...

This year's recipients have been recognised for their work on the HIV epidemic, GLP-1-based drugs, and how DNA can stimulate ...

If approved, lenacapavir would be the first and only twice-yearly HIV prevention choice for people who need or want PrEP.

Current INSTI vs protease inhibitor or NNRTI use is linked to an increased risk for diabetes, which is slightly attenuated when adjusted for changes in BMI.

Gilead Sciences’ shares closed up 2.7% at $83.16 yesterday, after it releases positive results of an interim analysis from a ...

Patients with HIV treated with antiretroviral therapy (ART) have a 31.5% chance of being anemic with many significantly ...

Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for ...

The Lasker Foundation today announced the winners of its 2024 Lasker Awards. Quarraisha Abdool Karim and Salim S. Abdool ...

Could declines in serum hepatitis B virus RNA during the first and second year of treatment with nucleoside analogues be ...

Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, ...

We are deeply honoured and humbled to be recipients of this prestigious award that recognises our and the CAPRISA team, ...

The Therapeutic Goods Administration confirmed to news.com.au it was aware of shortages of multiple brands of tenofovir/emtricitabine combination tablets, which is used for pre-exposure ...